Intellia Q1 loss narrows; Phase 3 HAE data positive, rolling BLA initiated

Intellia Therapeutics, Inc.

2026-Q1 EPS reported -$0.81 revenue$15,048,000

Net loss $96.2M vs $114.3M YoY; revenue $15.0M (down from $16.6M).
Phase 3 HAELO topline: lonvo-z reduced HAE attacks 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
Rolling BLA for lonvo-z initiated; completion H2 2026 for potential US launch H1 2027.
Cash $517.2M at Mar 31; April offering raised ~$207M gross; runway into 2028 excluding lonvo-z revenue.
FDA lifted clinical holds on nex-z Phase 3 trials (MAGNITUDE/MAGNITUDE-2); patient screening resumed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Intellia Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $15.0 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $15.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

commercial launch for HAE in the first half of 2027. This guidance excludes all potential commercial revenues from lonvo-z. • Collaboration Revenue : Collaboration revenue was $15.0 million for the first quarter of 2026, compared to $16.6 million for the first quarter of 2025. • R&D Expenses : Research and development (R&D) expenses were $80.7 million for the first

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-215721

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.